SpineThera
SpineThera is a clinical-stage pharmaceutical company developing SX600, a sustained-release dexamethasone epidural injection using its proprietary Faros™ drug delivery platform to treat lumbar radicular pain (sciatica), an indication with no current FDA-approved drug therapy.
- Company typePrivate
- Founded2012
- HeadquartersPlymouth, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What SpineThera does
SpineThera is a clinical-stage pharmaceutical company developing sustained-release injectable drugs for pain management. Its lead asset, SX600, is a novel formulation of dexamethasone built on the proprietary Faros™ drug delivery platform, designed to provide months-long sustained release from a single epidural injection for the treatment of lumbar radicular pain (sciatica). The company is led by founder and CEO Jeff Missling and Chief Medical Officer William Houghton. Notably, no FDA-approved drug currently exists for epidural injection to treat lumbar radicular pain, positioning SX600 as a potential first-in-class therapy for what the company characterizes as the most common cause of disability in the United States and the most expensive indication in healthcare.
The company's technology foundation is the Faros™ sustained-release drug delivery platform, protected by 7 issued US patents as of November 2024. SX600 completed Phase 2 clinical trials demonstrating clinically meaningful and durable pain reduction from a single injection; however, an additional non-rodent toxicology study is required before opening an IND to advance into Phase 3. SpineThera operates as a subsidiary within Frenelle Pharma's hub-and-spoke model, alongside portfolio companies Frenelle PBC and Anumio. In April 2024, SpineThera divested its manufacturing capabilities to ProMed Pharma while retaining an option for IP licensing, indicating a transition to an asset-light, R&D-focused operating model.
SpineThera's business model is pre-commercial and currently revenue-free. Historical funding has come from exempt securities offerings (a $4M Form D filed in June 2021, with $1.215M sold) and a $5M Department of Defense grant awarded in April 2022. Upon any future FDA approval, distribution is expected to flow through specialty pharmacies, hospital formularies, and pain management clinics. End customers are patients with lumbar radicular pain and the pain management specialists who administer treatment. The company has begun exploring adjacent applications of the Faros™ platform through a June 2024 collaboration with Mayo Clinic in substance abuse disorder treatment, signaling intent to monetize the delivery technology beyond its original indication.
SpineThera firmographics
Firmographics- Name
- SpineThera
- Legal name
- SpineThera, Inc.
- Website
- https://spinethera.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- SpineThera is a clinical-stage pharmaceutical company developing SX600, a sustained-release dexamethasone epidural injection using its proprietary Faros™ drug delivery platform to treat lumbar radicular pain (sciatica), an indication with no current FDA-approved drug therapy.
- Ownership category
- akta.pro rank
SpineThera industry classification
Industry- Product category
- Pain Management Pharmaceuticals
- akta.pro primary industry
- Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)
- akta.pro secondary industry
- Pain Medicine (Interventional/Neuropathic Pain) (HLAKAIAM)
Keywords
Where SpineThera is headquartered
LocationHeadquarters
- HQ city
- Plymouth
- HQ country
- United States
- HQ region
- North America
Markets served
SpineThera business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Pharmaceutical Product Sales: Pre-revenue clinical-stage company. Revenue will be generated through sales of FDA-approved pharmaceutical products, specifically SX600 for lumbar radicular pain treatment upon regulatory approval.
SpineThera product offering
Product offeringCore offering
SpineThera is developing SX600, a novel sustained-release formulation of dexamethasone administered as a single epidural injection for the treatment of lumbar radicular pain (sciatica). The product is built on the proprietary Faros™ drug delivery platform, which enables months-long therapeutic release of dexamethasone from a single injection, eliminating the need for repeated corticosteroid procedures. SX600 has completed Phase 2 clinical trials demonstrating clinically meaningful and durable pain reduction.
Product overview
SpineThera is a clinical-stage pharmaceutical company that operates as a subsidiary of Frenelle Pharma. The company is developing SX600, a novel formulation of dexamethasone utilizing the proprietary Faros™ sustained-release drug delivery technology platform. SX600 is designed as an epidural injection for lumbar radicular pain (sciatica) and has completed Phase 2 clinical trials. Currently, there is no FDA-approved drug for epidural injection to treat lumbar radicular pain, representing a potential first-in-class opportunity. The company's pipeline progresses from preclinical through Phase 3 stages.
Differentiator
Problem solved
Functional benefit
Brands
- Faros™: Proprietary technology platform used for sustained-release drug delivery in SpineThera's lead asset SX600.
- SX600
Products and services
- SX600 Novel sustained-release formulation of dexamethasone using Faros™ technology, developed as a single epidural injection for the treatment of lumbar radicular pain (sciatica). Designed to deliver months-long sustained-release dexamethasone from a single injection, eliminating the need for repeated corticosteroid procedures. Completed Phase 2 clinical trials with positive efficacy data. Intended for prescription and administration by pain management specialists and healthcare providers.
- Faros™ Drug Delivery Technology Platform Proprietary sustained-release drug delivery technology platform enabling months-long release of therapeutic agents (such as dexamethasone) from a single injection. Offered as a licensable platform to pharmaceutical partners; ProMed Pharma acquired an option to license the underlying intellectual property in April 2024.
Quantifiable outcome
- Clinically meaningful and durable reduction in lumbar radicular pain from a single epidural injection in Phase 2 trial
Companies that use SpineThera
Customer profileSegments2 records
Ideal customer profiles2 records
SpineThera technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
SpineThera partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Mayo CliniccoreSpineThera, Inc. entered into a collaboration with Mayo Clinic in June 2024 to advance solutions in substance abuse disorder treatment, expanding beyond the company's core focus on back pain treatment.
- ProMed PharmacoreProMed Pharma acquired SpineThera's manufacturing capabilities and obtained an option to license intellectual property in April 2024, enabling ProMed to leverage SpineThera's production capabilities while SpineThera gains access to ProMed's manufacturing infrastructure.
- Frenelle PharmacoreSpineThera operates as a portfolio company under Frenelle Pharma, a hub-and-spoke pharmaceutical model company. Frenelle Pharma officially launched in January 2025, with SpineThera representing one of its key pipeline assets.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
SpineThera competitors and assessment
Company assessmentDirect peers
- Pacira Biosciences: Pacira is a specialty pharmaceutical company known for sustained-release injectable pain therapies (e.g., Exparel). It is the most directly comparable peer to SpineThera given the overlap in sustained-release injectable technology and non-opioid pain focus.
- Heron Therapeutics: Heron develops sustained-release and long-acting injectable therapeutics for postoperative pain and other indications (e.g., Zynrelef, Sustol). The company's extended-release drug delivery approach for pain management closely parallels SpineThera's Faros™ technology strategy.
- Collegium Pharmaceutical: Collegium is a specialty pharmaceutical company focused on responsible pain management, including abuse-deterrent and non-opioid pain products. It targets overlapping physician channels (pain specialists, prescribers) as SpineThera's SX600.
- Scilex Holding: Scilex Holding is a specialty pharma company focused on non-opioid pain management, including sciatica and lower back pain (e.g., ZTlido, SP-102). It is a direct competitor targeting the same lumbar radicular pain indication via interventional/injectable therapies.
- Cara Therapeutics: Cara Therapeutics develops therapeutics for pruritus and pain, with focus on novel peripherally acting kappa opioid receptor agonists. It operates in the same clinical-stage pain therapeutics space as SpineThera with similar development and commercialization challenges.
- Trevena: Trevena is a clinical-stage pharmaceutical company developing innovative pain therapeutics, including Olinvyk (an IV analgesic). It overlaps with SpineThera in developing differentiated, non-opioid pain management options for acute and chronic indications.
- Tersera Therapeutics: Tersera is a specialty pharmaceutical company focused on pain management, oncology, and supportive care. Its pain franchise targets similar specialist prescribers and represents commercial overlap with a future SX600 launch.
Broad incumbents
- Pfizer: Pfizer is a large incumbent pharmaceutical company with a broad pain portfolio (including Lyrica and Celebrex historically) and deep commercialization capability. It represents both a potential acquirer of SpineThera and a broad competitive threat once SX600 reaches market.
- Vertex Pharmaceuticals: Vertex is a large pharmaceutical company that has publicly expanded into acute and chronic pain (e.g., VX-548/suzetrigine). Although Vertex's modality differs (oral NaV1.8 inhibitor), it is competing in the same non-opioid pain treatment market SpineThera targets.
- Eli Lilly: Lilly is a large pharmaceutical incumbent with an expanding pain and neuroscience portfolio. As a potential strategic acquirer or competitor, Lilly represents the kind of large-pharma counterparty likely to evaluate SpineThera's first-in-class epidural asset.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat2 records
Key risks6 records
Key highlights6 records
Customer concentration
SpineThera social profiles
Digital presenceSpineThera financial estimates
Financial estimateRevenue estimate
Valuation estimate
SpineThera leadership team
Management profileNumber of profiles
Profiles2 records
SpineThera funding detail
Funding detailFunding overview
Funding rounds11 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SpineThera M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SpineThera
What does SpineThera do?
SpineThera is developing SX600, a novel sustained-release formulation of dexamethasone administered as a single epidural injection for the treatment of lumbar radicular pain (sciatica). The product is built on the proprietary Faros™ drug delivery platform, which enables months-long therapeutic release of dexamethasone from a single injection, eliminating the need for repeated corticosteroid procedures. SX600 has completed Phase 2 clinical trials demonstrating clinically meaningful and durable pain reduction.
Is SpineThera a public or private company?
SpineThera is a private company. It is classified as corporate owned and is currently operating.
When was SpineThera founded?
SpineThera was founded in 2012. It employs 1 to 10 people.
Where is SpineThera based?
SpineThera is headquartered in Plymouth, United States, in the North America region.
How does SpineThera make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are SpineThera's main competitors?
Direct peers on record are Pacira Biosciences, Heron Therapeutics, Collegium Pharmaceutical, Scilex Holding, Cara Therapeutics, Trevena and Tersera Therapeutics. Broad incumbents are Pfizer, Vertex Pharmaceuticals and Eli Lilly.
Does SpineThera have an API?
No public API is recorded for SpineThera.
What industry is SpineThera in?
SpineThera's product category is Pain Management Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAN, Pain Management & Anesthesiology Pharmaceuticals, with a secondary code of HLAKAIAM, Pain Medicine (Interventional/Neuropathic Pain).